ELVN
Price
$18.23
Change
+$0.46 (+2.59%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
880.61M
14 days until earnings call
VYNE
Price
$1.87
Change
+$0.03 (+1.63%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
28.29M
Ad is loading...

ELVN vs VYNE

Header iconELVN vs VYNE Comparison
Open Charts ELVN vs VYNEBanner chart's image
Enliven Therapeutics
Price$18.23
Change+$0.46 (+2.59%)
Volume$9.45K
Capitalization880.61M
VYNE Therapeutics
Price$1.87
Change+$0.03 (+1.63%)
Volume$2.9K
Capitalization28.29M
ELVN vs VYNE Comparison Chart
Loading...
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVN vs. VYNE commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVN is a StrongBuy and VYNE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ELVN: $17.71 vs. VYNE: $1.85)
Brand notoriety: ELVN and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVN: 66% vs. VYNE: 43%
Market capitalization -- ELVN: $880.61M vs. VYNE: $28.29M
ELVN [@Biotechnology] is valued at $880.61M. VYNE’s [@Biotechnology] market capitalization is $28.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVN’s FA Score shows that 0 FA rating(s) are green whileVYNE’s FA Score has 1 green FA rating(s).

  • ELVN’s FA Score: 0 green, 5 red.
  • VYNE’s FA Score: 1 green, 4 red.
According to our system of comparison, VYNE is a better buy in the long-term than ELVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELVN’s TA Score shows that 6 TA indicator(s) are bullish while VYNE’s TA Score has 5 bullish TA indicator(s).

  • ELVN’s TA Score: 6 bullish, 3 bearish.
  • VYNE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ELVN is a better buy in the short-term than VYNE.

Price Growth

ELVN (@Biotechnology) experienced а +10.21% price change this week, while VYNE (@Biotechnology) price change was +2.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was -6.02%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

ELVN is expected to report earnings on Aug 07, 2025.

VYNE is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELVN($881M) has a higher market cap than VYNE($28.3M). ELVN YTD gains are higher at: -21.289 vs. VYNE (-44.776). VYNE has higher annual earnings (EBITDA): -43.63M vs. ELVN (-104.24M). ELVN has more cash in the bank: 313M vs. VYNE (61.5M). ELVN has less debt than VYNE: ELVN (0) vs VYNE (99K). VYNE has higher revenues than ELVN: VYNE (501K) vs ELVN (0).
ELVNVYNEELVN / VYNE
Capitalization881M28.3M3,113%
EBITDA-104.24M-43.63M239%
Gain YTD-21.289-44.77648%
P/E RatioN/A0.71-
Revenue0501K-
Total Cash313M61.5M509%
Total Debt099K-
FUNDAMENTALS RATINGS
VYNE: Fundamental Ratings
VYNE
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELVNVYNE
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 10 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 17 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TPST7.890.31
+4.09%
Tempest Therapeutics Inc
BV13.550.27
+2.03%
BrightView Holdings
CLAR3.410.06
+1.79%
Clarus Corp
CSGP81.830.96
+1.19%
CoStar Group
WTM1751.006.40
+0.37%
White Mountains Insurance Group Ltd

ELVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with ERAS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
-1.45%
ERAS - ELVN
50%
Loosely correlated
+2.90%
APGE - ELVN
49%
Loosely correlated
+2.93%
CRNX - ELVN
48%
Loosely correlated
+3.55%
DNLI - ELVN
47%
Loosely correlated
+1.85%
COGT - ELVN
47%
Loosely correlated
+3.00%
More

VYNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with IRON. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then IRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
-0.54%
IRON - VYNE
39%
Loosely correlated
+2.59%
ELVN - VYNE
35%
Loosely correlated
-1.45%
TPST - VYNE
34%
Loosely correlated
+4.09%
KOD - VYNE
34%
Loosely correlated
+9.62%
TRDA - VYNE
33%
Poorly correlated
N/A
More